Amyloid Imaging with PET in Alzheimer’s Disease, Mild Cognitive Impairment, and Clinically Unimpaired Subjects

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-0-387-76420-7_6
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Frequent amyloid deposition without significant cognitive impairment among the elderly.

  2008cited by this paper
• Overview of protein aggregation in single, double, and triple neurodegenerative brain amyloidoses

  2007cited by this paper
• [11C]PIB in a nondemented population

  2006cited by this paper
• A specific amyloid-β protein assembly in the brain impairs memory

  2006cited by this paper
• Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease

  2006cited by this paper
• [O-15] Water and PIB PET imaging in Alzheimer's disease and mild cognitive impairment

  2006cited by this paper
• Development of a Monoclonal Antibody Specific for @3/A4Amyloid in Alzheimer's Disease Brain for Application to In Vivo Imaging of Amyloid Angiopathy

  2006cited by this paper
• Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans

  2006cited by this paper
• Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis

  2005cited by this paper
• Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis.

  2005cited by this paper
• Safety, Tolerability, and Changes in Amyloid β Concentrations After Administration of a γ-Secretase Inhibitor in Volunteers

  2005cited by this paper
• Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial

  2005cited by this paper
• Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B

  2005cited by this paper
• Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid-β in Alzheimer's Disease Brain But Not in Transgenic Mouse Brain

  2005cited by this paper
• Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease

  2005cited by this paper
• Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease

  2005cited by this paper
• Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease.

  2005cited by this paper
• Mild cognitive impairment as a diagnostic entity

  2004cited by this paper
• Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease.

  2004cited by this paper
• Neuropathology and Pathogenesis of Encephalitis following Amyloid β Immunization in Alzheimer's Disease

  2004cited by this paper
• Crystallization of glycosylated human BACE protease domain expressed in Trichoplusia ni.

  2004cited by this paper
• In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET.

  2004cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004cited by this paper
• Modified Bielschowsky stain and immunohistochemical studies on striatal plaques in Alzheimer's disease

  2004cited by this paper
• Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated byβ protein immunostain

  2004cited by this paper
• Toward modeling hemorrhagic and encephalitic complications of Alzheimer amyloid-beta vaccination in nonhuman primates.

  2004cited by this paper
• Conformation-dependent antibodies target diseases of protein misfolding.

  2004cited by this paper
• Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

  2004cited by this paper
• Imaging β-Amyloid Plaques and Neurofibrillary Tangles in the Aging Human Brain

  2004cited by this paper
• Slow Cognitive Decline in Alzheimer’s Disease

  2003cited by this paper
• Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report

  2003cited by this paper
• Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization

  2003cited by this paper
• Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders.

  2003cited by this paper
• Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 1.

  2003cited by this paper
• Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.

  2003cited by this paper
• Structure-activity relationship of imidazo[1,2-a]pyridines as ligands for detecting beta-amyloid plaques in the brain.

  2003cited by this paper
• Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-β ligand in transgenic mice

  2003cited by this paper
• The Binding of 2-(4′-Methylaminophenyl)Benzothiazole to Postmortem Brain Homogenates Is Dominated by the Amyloid Component

  2003cited by this paper
• Education modifies the relation of AD pathology to level of cognitive function in older persons

  2003cited by this paper
• JLK isocoumarin inhibitors: Selective γ‐secretase inhibitors that do not interfere with notch pathway in vitro or in vivo

  2003cited by this paper
• 11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease.

  2003cited by this paper
• Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology

  2003cited by this paper
• Incidence and outcome of mild cognitive impairment in a population-based prospective cohort

  2002cited by this paper
• Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo

  2002cited by this paper
• Imaging Aβ Plaques in Living Transgenic Mice with Multiphoton Microscopy and Methoxy‐X04, a Systemically Administered Congo Red Derivative

  2002cited by this paper
• What is cognitive reserve? Theory and research application of the reserve concept

  2002cited by this paper
• A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain.

  2002cited by this paper
• Synthesis and evaluation of 2-(3′-lodo-4′-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in alzheimer’s disease

  2002cited by this paper
• Secretases as targets for the treatment of Alzheimer's disease: the prospects.

  2002cited by this paper
• Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease.

  2002cited by this paper
• Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

  2002cited by this paper
• Phases of Aβ-deposition in the human brain and its relevance for the development of AD

  2002cited by this paper
• Synthesis and 11C-labelling of (E,E)-1-(3′,4′-dihydroxystyryl)-4-(3′-methoxy-4′-hydroxystyryl) benzene for PET imaging of amyloid deposits††

  2002cited by this paper
• IBOX(2-(4'-dimethylaminophenyl)-6-iodobenzoxazole): a ligand for imaging amyloid plaques in the brain.

  2001cited by this paper
• BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.

  2001cited by this paper
• Mild cognitive impairment represents early-stage Alzheimer disease.

  2001cited by this paper
• Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease

  2001cited by this paper
• Absence of cognitive impairment or decline in preclinical Alzheimer’s disease

  2001cited by this paper
• Binding Characteristics of Radiofluorinated 6-Dialkylamino-2-Naphthylethylidene Derivatives as Positron Emission Tomography Imaging Probes for β-Amyloid Plaques in Alzheimer's Disease

  2001cited by this paper
• Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain.

  2001cited by this paper
• Progress towards testing the amyloid hypothesis: inhibitors of APP processing.

  2001cited by this paper
• Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage alzheimer’s disease

  2001cited by this paper
• Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates.

  2001cited by this paper
• The Oregon Brain Aging Study

  2000cited by this paper
• Research evaluation and diagnosis of possible Alzheimer’s disease over the last two decades: II

  2000cited by this paper
• Regulation of APP cleavage by α‐, β‐ and γ‐secretases

  2000cited by this paper
• X-34, A Fluorescent Derivative of Congo Red: A Novel Histochemical Stain for Alzheimer's Disease Pathology

  2000cited by this paper
• FAD mutations in presenilin-1 or amyloid precursor protein decrease the efficacy of a gamma-secretase inhibitor: evidence for direct involvement of PS1 in the gamma-secretase cleavage complex.

  2000cited by this paper
• Targeting Alzheimer amyloid plaques in vivo

  2000cited by this paper
• Functional gamma‐secretase inhibitors reduce beta‐amyloid peptide levels in brain

  2000cited by this paper
• “Preclinical” AD revisited

  2000cited by this paper
• Relation of education to brain size in normal aging

  1999cited by this paper
• Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease

  1999cited by this paper
• Alzheimer neuropathologic alterations in aged cognitively normal subjects.

  1999cited by this paper
• Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer’s Disease

  1999cited by this paper
• 18F-FDG PET imaging of muscle activity in runners.

  1999cited by this paper
• Progression of regional neuropathology in Alzheimer disease and normal elderly: findings from the Nun study.

  1999cited by this paper
• The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease

  1999cited by this paper
• 99mTc-MAMA-chrysamine G, a probe for beta-amyloid protein of Alzheimer’s disease

  1999cited by this paper
• Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals.

  1998cited by this paper
• Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease.

  1998cited by this paper
• Mutant genes in familial Alzheimer's disease and transgenic models.

  1998cited by this paper
• Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau

  1998cited by this paper
• Biological markers of Alzheimer's disease.

  1998cited by this paper
• The effects of intelligence and education on the development of dementia. A test of the brain reserve hypothesis

  1997cited by this paper
• Neuroimaging of Vessel Amyloid in Alzheimer's Disease a, b

  1997cited by this paper
• Diagnostic criteria for Alzheimer's disease.

  1997cited by this paper
• The distribution of amyloid β protein deposition in the corpus striatum of patients with Alzheimer's disease

  1997cited by this paper
• REVIEWThe Gene Defects Responsible for Familial Alzheimer's Disease

  1996cited by this paper
• Intra-arterial infusion of [125I]A beta 1-40 labels amyloid deposits in the aged primate brain in vivo.

  1996cited by this paper
• Cerebral amyloid deposition and diffuse plaques in ``normal'' aging

  1996cited by this paper
• Chrysamine-G binding to Alzheimer and control brain: autopsy study of a new amyloid probe.

  1995cited by this paper
• Neuropathological changes in Down's syndrome hippocampal formation. Effect of age and apolipoprotein E genotype.

  1995cited by this paper
• Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex.

  1995cited by this paper
• Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43)

  1994cited by this paper
• Development of an anti-Aβ monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease

  1994cited by this paper
• Development and in vitro characterization of a cationized monoclonal antibody against beta A4 protein: a potential probe for Alzheimer's disease.

  1994cited by this paper
• Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease.

  1994cited by this paper
• Does variability increase with age? An archival study of cognitive measures.

  1993cited by this paper
• Tau Protein and the Neurofibrillary Pathology of Alzheimer's Disease

  1993cited by this paper

• Early Detection of Alzheimer's Disease using Machine Learning and Deep Learning Techniques

  2025cites this paper
• On the Inadequacy of the Current Transgenic Animal Models of Alzheimer’s Disease: The Path Forward

  2024cites this paper
• Alzheimer's Disease Detection Using Deep Learning on Neuroimaging: A Systematic Review

  2024cites this paper
• Implication of the cooking oil-peroxidation product “hydroxynonenal” for Alzheimer’s disease

  2023cites this paper
• Initial assessment of the spatial learning, reversal, and sequencing task capabilities of knock- in rats with humanizing mutations in the Aβ-coding region of App

  2022cites this paper
• A Dual-Pronged Approach: A Ruthenium(III) Complex That Modulates Amyloid-β Aggregation and Disrupts Its Formed Aggregates.

  2022cites this paper
• The Amyloid Cascade Hypothesis 2.0: On the Possibility of Once-in-a-Lifetime-Only Treatment for Prevention of Alzheimer’s Disease and for Its Potential Cure at Symptomatic Stages

  2022cites this paper
• The Amyloid Cascade Hypothesis 2.0: Generalization of the Concept

  2022cites this paper
• Amyloid-β, tau, and the cholinergic system in Alzheimer’s disease: seeking direction in a tangle of clues

  2020cites this paper
• A guide to using functional magnetic resonance imaging to study Alzheimer's disease in animal models

  2018cites this paper
• Exploring the Role of Somatostatin in the Pathogenesis of Alzheimer’s disease

  2018cites this paper
• Investigating how APOE differentially affects memory and perception of ambiguous scenes in young- and middle-aged adults

  2018cites this paper
• The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind

  2017cites this paper
• Recent Perspective About the Amyloid Cascade Hypothesis and Stem Cell-Based Therapy in the Treatment of Alzheimer's Disease

  2016cites this paper
• The case for rejecting the amyloid cascade hypothesis

  2015cites this paper